Paid Research Studies in New York

Condition:   Multiple Sclerosis
Intervention:   Other: MRI
Sponsors:   University at Buffalo;   University at Buffalo
Recruiting - verified June 2013

Condition:   Spinal Deformity
Intervention:  
Sponsors:   International Spine Study Group Foundation;   Shay Bess;   DePuy Spine
Not yet recruiting - verified June 2013

Condition:   Acne Vulgaris
Interventions:   Drug: CD0271 0.3% / CD1579 2.5%;   Drug: CD0271 0.1% / CD1579 2.5%;   Drug: Topical Gel Vehicle
Sponsors:   Galderma R&D;   Galderma R&D
Not yet recruiting - verified June 2013

Condition:   Depression
Interventions:   Drug: Ketamine and Lithium;   Drug: Ketamine and Placebo
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine
Not yet recruiting - verified June 2013

Condition:   Diabetes Mellitus
Intervention:   Other: Mobile Insulin Titration Intervention
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   New York City Health and Hospitals Corporation
Recruiting - verified June 2013

Conditions:   HIV;   Sexually Transmitted Infections;   Substance Use
Intervention:   Behavioral: MI + CBST Intervention
Sponsors:   Hunter College;   Hunter College;   National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2013

Condition:   Herpes Simplex Virus
Intervention:   Device: Genexpert assay
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Not yet recruiting - verified June 2013

Condition:   Low Risk Prostate Cancer
Intervention:   Behavioral: assessments
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Mount Sinai School of Medicine
Recruiting - verified June 2013

Conditions:   Colorectal Cancer;   Prevention
Interventions:   Behavioral: Motivational Interviewing;   Behavioral: Attention Control
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine;   American Cancer Society, Inc.
Not yet recruiting - verified June 2013

Conditions:   Neurofibromatosis Type 2;   Vestibular Schwannomas;   Meningiomas
Intervention:   Drug: RAD001 10mg p.o. daily
Sponsors:   New York University School of Medicine;   New York University School of Medicine
Recruiting - verified June 2013

Condition:   Recurrent Small Cell Lung Cancer
Interventions:   Drug: Etirinotecan pegol NKTR 102;   Other: pharmacogenomic studies;   Other: laboratory biomarker analysis
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Nektar Therapeutics
Not yet recruiting - verified June 2013

Condition:   Chronic Obstructive Pulmonary Disease (COPD)
Intervention:  
Sponsors:   University of Michigan;   University of Michigan;   United BioSource Corporation;   National Institutes of Health (NIH)
Recruiting - verified June 2013

Conditions:   Hypogonadism;   Opioid-Related Disorders;   Male Infertility
Interventions:   Drug: Clomiphene citrate;   Drug: Placebo
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Not yet recruiting - verified June 2013

Condition:   Adhesive Capsulitis
Interventions:   Device: Dynasplint;   Other: Standard of Care
Sponsors:   Dynasplint Systems, Inc.;   Dynasplint Systems, Inc.
Recruiting - verified June 2013

Condition:   Diabetic Nephropathies
Interventions:   Drug: BAY94-8862;   Drug: Placebo
Sponsors:   Bayer;   Bayer
Not yet recruiting - verified June 2013

Conditions:   Dilated Cardiomyopathy;   Hypertrophic Cardiomyopathy;   Restrictive Cardiomyopathy
Intervention:  
Sponsors:   University of Miami;   University of Miami;   New England Research Institutes;   Children's Hospital Medical Center, Cincinnati;   Washington University School of Medicine;   Children's Hospital of Philadelphia;   Columbia University;   Children's Hospital Boston;   Ann & Robert H Lurie Children's Hospital of Chicago;   Primary Children's Medical Center;   Monroe Carell Jr Children's Hospital at Vanderbilt;   Stollery Children's Hospital
Recruiting - verified June 2013

Conditions:   Dilated Cardiomyopathy;   Hypertrophic Cardiomyopathy
Intervention:  
Sponsors:   University of Miami;   University of Miami;   New England Research Institutes;   Washington University School of Medicine;   Children's Hospital Boston;   Columbia University;   Children's Hospital of Philadelphia;   Ann & Robert H Lurie Children's Hospital of Chicago;   Primary Children's Medical Center;   Monroe Carell Jr Children's Hospital at Vanderbilt;   Stollery Children's Hospital;   Children's Hospital Medical Center, Cincinnati;   Montefiore Medical Center
Not yet recruiting - verified June 2013

Condition:   Hodgkin Disease
Interventions:   Drug: brentuximab vedotin;   Drug: bendamustine
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified June 2013

Conditions:   Hematopoietic Stem Cell Transplantation;   Breast Cancer;   Fatigue;   Mild Cognitive Impairment;   Light;   Quality of Life;   Sleep
Interventions:   Device: Bright white light;   Device: Dim red light
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine;   National Cancer Institute (NCI);   University of California, San Diego;   Hackensack University Medical Center
Recruiting - verified June 2013

Condition:   Germ Cell Tumors
Interventions:   Drug: Paclitaxel;   Drug: Ifosfamide;   Drug: Cisplatin;   Drug: Mesna;   Drug: Bleomycin;   Drug: Etoposide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   University of Southern California;   Mayo Clinic;   University of Pittsburgh;   University of North Carolina;   University of Chicago;   Stanford University
Recruiting - verified June 2013

Conditions:   Atrial Fibrillation;   Hypertension
Interventions:   Procedure: catheter ablation;   Procedure: renal sympathetic denervation
Sponsors:   Meshalkin Research Institute of Pathology of Circulation;   Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified June 2013

Condition:   Idiopathic Pulmonary Fibrosis
Interventions:   Drug: lebrikizumab;   Drug: placebo
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified June 2013

Conditions:   Insulin Resistance;   Glucose Intolerance;   Obesity;   Atherosclerosis
Interventions:   Device: Reactive hyperemia peripheral artery tonometry (Rh-PAT);   Other: Blood levels for glucose, insulin, lipids and adipocytokines
Sponsors:   Montefiore Medical Center;   Montefiore Medical Center
Recruiting - verified June 2013

Condition:   Internet and Mobile Technology Use
Intervention:   Other: Pilot Health Website
Sponsors:   Columbia University;   Columbia University;   National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified June 2013

Condition:   Smoking Cessation
Interventions:   Behavioral: Brief Treatment (BT);   Behavioral: Intensive Treatment (IT)
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Cancer Institute (NCI);   National Institutes of Health (NIH)
Not yet recruiting - verified June 2013

Conditions:   Hepatocellular Carcinoma;   HCC
Intervention:   Device: Magnetic Resonance Imaging
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine
Recruiting - verified June 2013

Condition:   Spondylitis, Ankylosing
Interventions:   Drug: Ixekizumab;   Drug: Placebo;   Drug: Adalimumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified June 2013

Condition:   Surgical Site Infection Following Cesarean Delivery
Interventions:   Drug: Iodine povidone;   Drug: Chlorhexidine;   Drug: Combination iodine and chlorhexidine
Sponsors:   Montefiore Medical Center;   Montefiore Medical Center
Recruiting - verified June 2013

Condition:   Memory Deficits Associated With ECT.
Interventions:   Behavioral: Cognitive Intervention: Memory Training;   Behavioral: Comparable general mental stimulation
Sponsors:   New York State Psychiatric Institute;   New York State Psychiatric Institute
Recruiting - verified June 2013

Conditions:   Schizophrenia;   Schizoaffective Disorder;   Psychotic Disorder NOS;   Bipolar Disorder With Psychotic Features
Intervention:   Drug: risperidone
Sponsors:   North Shore Long Island Jewish Health System;   North Shore Long Island Jewish Health System
Recruiting - verified June 2013

Condition:   Need for IV Access
Interventions:   Device: Long axis IV placement with ultrasound;   Device: Short axis IV placement with ultrasound
Sponsors:   Beth Israel Medical Center;   Beth Israel Medical Center
Recruiting - verified June 2013

Condition:   Metastatic or Locally-advanced Unresectable Breast Cancer
Interventions:   Drug: BYL719;   Drug: Letrozole;   Drug: Exemestane
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Condition:   Basal Cell Carcinoma
Intervention:  
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Overactive Bladder
Interventions:   Drug: dexmecamylamine;   Drug: Placebo
Sponsors:   Targacept Inc.;   Targacept Inc.
Recruiting - verified June 2013

Condition:   Hodgkin Lymphoma
Interventions:   Drug: Brentuximab vedotin (SGN-35);   Drug: Doxorubicin HCL;   Drug: Vinblastine Sulfate;   Device: Dacarbazine;   Radiation: Involved-Site Radiation Therapy (ISRT);   Procedure: Interim PET
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Seattle Genetics, Inc.
Recruiting - verified May 2013

Condition:   Open-angle Glaucoma or Ocular Hypertension
Interventions:   Drug: DE-117 ophthalmic solution;   Drug: latanoprost ophthalmic solution;   Other: Placebo
Sponsors:   Santen Inc.;   Santen Inc.
Recruiting - verified June 2013

Condition:   Pain
Intervention:   Drug: Ropivacaine 0.5% 20cc injectate bilaterally
Sponsors:   Montefiore Medical Center;   Montefiore Medical Center
Recruiting - verified May 2013

Condition:   Smoker
Interventions:   Other: Cigarettes;   Other: Snus
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Not yet recruiting - verified May 2013

Condition:   Relapsed or Refractory Multiple Myeloma
Intervention:   Drug: Cabozantinib (XL184)
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Exelixis
Recruiting - verified May 2013

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: LY2922470
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified June 2013

Condition:   Persistent Atrial Fibrillation
Intervention:   Procedure: Ablation
Sponsors:   Valley Health System;   Valley Health System;   Massachusetts General Hospital;   Long Island Jewish Hospital;   State Research Institute of Circulation Pathology
Recruiting - verified June 2013

Conditions:   Degenerative Changes;   Stenosis;   Spondylosis
Intervention:   Device: OsteoStrux Collagen Ceramic Scaffold
Sponsors:   Integra LifeSciences Corporation;   Integra LifeSciences Corporation
Recruiting - verified June 2013

Condition:   Newly Diagnosed Ewing Sarcoma
Interventions:   Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2013

Conditions:   Microbiota;   Lung Cancer;   Oral Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2013

Condition:   Skin Diseases
Intervention:  
Sponsors:   U.S. Army Medical Research and Materiel Command;   U.S. Army Medical Research and Materiel Command;   InBIOS
Not yet recruiting - verified May 2013

Condition:   Breast Cancer
Interventions:   Procedure: Positron Emission Tomography (PET);   Drug: Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC);   Procedure: Positron emission mammography (PEM) When available;   Procedure: MR
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   GE Healthcare
Recruiting - verified June 2013

Conditions:   Hypertension;   Substance Abuse;   Asthma;   Depression
Intervention:  
Sponsors:   Yale University;   Yale University
Not yet recruiting - verified May 2013

Condition:   Cystic Fibrosis
Interventions:   Other: Ophthalmologic examinations;   Drug: Ivacaftor Exposed
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated;   Cystic Fibrosis Foundation
Recruiting - verified June 2013

Condition:   Breast Cancer
Interventions:   Drug: GDC-0032;   Drug: GDC-0032;   Drug: Docetaxel;   Drug: Paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2013

Condition:   Dysphagia
Intervention:   Other: Cold Thin Liquid Barium
Sponsors:   Winthrop University Hospital;   Winthrop University Hospital
Not yet recruiting - verified May 2013

Conditions:   Depression;   Major Depressive Episode;   Bipolar Disorder
Interventions:   Device: MagVenture MagPro MST;   Device: RUL ECT
Sponsors:   New York State Psychiatric Institute;   New York State Psychiatric Institute
Recruiting - verified May 2013

Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Myelogenous Leukemia, Acute, Childhood
Interventions:   Drug: Azacitidine;   Drug: Fludarabine;   Drug: Cytarabine
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   Gateway for Cancer Research;   USC/Norris Comprehensive Cancer Center
Not yet recruiting - verified May 2013

Condition:   Post-operative Pain
Interventions:   Drug: Marcaine- 0.25%;   Drug: Marcaine 0.25%.
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified May 2013

Condition:   Marijuana Smoking
Intervention:   Behavioral: Personalized Feedback and Exercise
Sponsors:   State University of New York at Buffalo;   State University of New York at Buffalo
Not yet recruiting - verified May 2013

Conditions:   Essential Voice Tremor;   Vocal Tremor;   Voice Tremor;   Essential Tremor of Voice
Intervention:   Drug: Octanoic acid
Sponsors:   Syracuse University;   Syracuse University;   National Institute on Deafness and Other Communication Disorders (NIDCD)
Not yet recruiting - verified May 2013

Condition:   The Focus of Study Will be on a New Imaging Modality.
Intervention:   Other: 3D Sonography analysis
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Condition:   Relapsed B-Cell Acute Lymphoblastic Leukemia
Interventions:   Procedure: leukapheresis or collection of PBMCs;   Drug: cyclophosphamide;   Biological: modified T cells
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Tubal Patency
Intervention:   Device: FemVue device
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Condition:   Atopic Dermatitis
Interventions:   Drug: Dupilumab (REGN668/ SAR231893);   Drug: Placebo
Sponsors:   Regeneron Pharmaceuticals;   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified May 2013

Condition:   Back Pain Lower Back Chronic
Interventions:   Device: Custom Foot Orthotic;   Device: Sham Orthotic
Sponsors:   Canandaigua VA Medical Center;   Canandaigua VA Medical Center;   Foot Levelers, Inc.;   New York Chiropractic College
Recruiting - verified May 2013

Conditions:   Major Depressive Disorder;   Dysthymia
Interventions:   Behavioral: Cognitive Behavior Therapy for Depression;   Behavioral: Cognitive Behavior Therapy for Depression
Sponsors:   New York State Psychiatric Institute;   New York State Psychiatric Institute
Recruiting - verified May 2013

Conditions:   Full Iris Defects;   Partial Iris Defects
Intervention:   Device: Artificial Iris (CustomFlex)
Sponsors:   HumanOptics AG;   HumanOptics AG
Not yet recruiting - verified June 2013

Condition:   Disruptive Mood Dysregulation Disorder
Interventions:   Behavioral: Dialectical Behavior Therapy for children;   Behavioral: Treatment as Usual
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified May 2013

Conditions:   Intrahepatic Cholangiocarcinoma;   Peripheral Cholangiocarcinoma;   Cholangiolar Carcinoma;   Cholangiocellular Carcinoma
Interventions:   Drug: Floxuridine (FUDR);   Drug: dexamethasone;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Other: MRI;   Other: Research blood draws
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2013

Condition:   Neuronal Ceroid Lipofuscinosis
Intervention:  
Sponsors:   University of Rochester;   University of Rochester;   Rare Diseases Clinical Research Network;   National Center for Advancing Translational Science (NCATS);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2013

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Tarceva (erlotinib)
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   Albert Einstein College of Medicine of Yeshiva University;   Beth Israel Medical Center;   Columbia University
Not yet recruiting - verified May 2013

Conditions:   Hepatitis C;   Medication Adherence
Intervention:   Other: Intensive Models (mDOT and CGT) of HCV Care
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting - verified May 2013

Conditions:   Psoriasis;   Cardiovascular Disease
Intervention:   Drug: Adalimumab
Sponsors:   University of Pennsylvania;   University of Pennsylvania;   AbbVie
Recruiting - verified April 2013

Conditions:   Age Related Macular Degeneration;   Choroidal Neovascularization;   Central Serous Chorioretinopathy
Intervention:  
Sponsors:   Sequenom, Inc.;   Sequenom, Inc.;   Vitreous -Retina- Macula Consultants of New York
Recruiting - verified June 2013

Condition:   Migraine
Intervention:   Device: Stimulation of the Occipital Nerves
Sponsors:   Ethicon, Inc.;   Ethicon, Inc.
Recruiting - verified June 2013

Condition:   Lymphoma
Interventions:   Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharmacyclics
Not yet recruiting - verified June 2013

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: GFF MDI;   Drug: GP MDI;   Drug: FF MDI;   Drug: Open-label tiotropium bromide inhalation powder;   Drug: Placebo MDI
Sponsors:   Pearl Therapeutics, Inc.;   Pearl Therapeutics, Inc.
Recruiting - verified June 2013

Condition:   Hepatitis C
Intervention:   Drug: SOF in combination with GS-5816
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified June 2013

Conditions:   Wrinkles;   Rhytides
Intervention:   Device: TriActive+ RF
Sponsors:   El. En. SpA;   El. En. SpA
Recruiting - verified June 2013

Condition:   Congestive Heart Failure
Interventions:   Drug: D-ribose;   Other: Placebo
Sponsors:   RiboCor, Inc.;   RiboCor, Inc.
Not yet recruiting - verified May 2013

Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Drug: GM604
Sponsors:   Genervon Biopharmaceuticals, LLC;   Genervon Biopharmaceuticals, LLC;   Columbia University;   Massachusetts General Hospital
Not yet recruiting - verified June 2013

Condition:   Peripheral Arterial Occlusive Disease
Intervention:   Other: PAD endovascular treatments
Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Systems Inc
Recruiting - verified June 2013

Condition:   Schizophrenia
Intervention:   Drug: Brexpiprazole 1mg to 4mg
Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Not yet recruiting - verified May 2013

Condition:   Sporadic Amyotrophic Lateral Sclerosis
Interventions:   Drug: Mexiletine;   Drug: Placebo
Sponsors:   University of Washington;   University of Washington
Not yet recruiting - verified May 2013

Condition:   Chronic Hepatitis C Virus
Interventions:   Drug: Sofosbuvir/Ledipasvir 400/90 mg;   Drug: Ribavirin
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified May 2013

Conditions:   Acquired Immune Deficiency Syndrome (AIDS);   HIV Infections
Intervention:   Drug: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified June 2013

Conditions:   Thyroid Associated Ophthalmopathies;   Thyroid-Associated Ophthalmopathy
Interventions:   Drug: teprotumumab;   Drug: Placebo
Sponsors:   River Vision Development Corporation;   River Vision Development Corporation
Recruiting - verified June 2013

Condition:   Hyperlipidemia and Mixed Dyslipidemia
Interventions:   Drug: AMG 145 and standard of care;   Other: Standard of care
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: MPDL3280A
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2013

Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: Commercial Hylenex® recombinant (hyaluronidase human injection);   Drug: Pre-commercial formulation of Hylenex recombinant (hyaluronidase human injection);   Procedure: Preadministration of commercial Hylenex® recombinant (hyaluronidase human injection);   Procedure: Preadministration of pre-commercial Hylenex recombinant (hyaluronidase human injection);   Device: Continuous Subcutaneous Insulin Infusion (CSII) via insulin infusion pumps
Sponsors:   Halozyme Therapeutics;   Halozyme Therapeutics
Recruiting - verified June 2013

Condition:   Smoking, Marijuana
Intervention:   Drug: cannabidiol
Sponsors:   National Institute on Drug Abuse (NIDA);   Steve Sparenborg
Not yet recruiting - verified May 2013

Condition:   Quality of Post-cesarean Analgesia During the 2nd 24 Hours After Surgery
Interventions:   Drug: Epidural Morphine;   Drug: Epidural Saline
Sponsors:   Columbia University;   Columbia University
Recruiting - verified June 2013

Condition:   Generalized Anxiety Disorder
Interventions:   Drug: Placebo;   Drug: Vilazodone
Sponsors:   Forest Laboratories;   Forest Laboratories
Recruiting - verified May 2013

Condition:   Barrett's Esophagus
Intervention:   Device: trūFreeze™ Spray Cryotherapy
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   CSA Medical, Inc.
Recruiting - verified June 2013

Condition:   Spinal Muscular Atrophy
Intervention:   Drug: ISIS-SMNRx
Sponsors:   Isis Pharmaceuticals;   Isis Pharmaceuticals
Recruiting - verified May 2013

Condition:   Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions:   Drug: Tremelimumab;   Drug: Placebo
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified May 2013

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: PEGPH20+nab-paclitaxel+gemcitabine;   Drug: nab-paclitaxel + gemcitabine
Sponsors:   Halozyme Therapeutics;   Halozyme Therapeutics
Recruiting - verified June 2013

Condition:   Multiple Myeloma
Intervention:  
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   AbbVie
Recruiting - verified June 2013

Condition:   Depression, Postpartum
Intervention:   Device: NeuroStar Transcranial Magnetic Stimulation (TMS)
Sponsors:   Neuronetics;   Neuronetics
Recruiting - verified June 2013

Condition:   Breast Cancer
Intervention:   Drug: Reparixin
Sponsors:   Dompé s.p.a.;   Dompé s.p.a.
Recruiting - verified May 2013

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: QVA149;   Drug: fluticasone/salmeterol
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified June 2013

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: BL-8040 +Ara-C
Sponsors:   BioLineRx, Ltd.;   BioLineRx, Ltd.
Recruiting - verified April 2013

Conditions:   Advanced Solid Tumor Cancer;   Metastatic Solid Tumor Cancer
Intervention:   Drug: CPI-613
Sponsors:   Cornerstone Pharmaceuticals, Inc.;   Cornerstone Pharmaceuticals, Inc.
Recruiting - verified June 2013

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: decitabine;   Other: laboratory biomarker analysis
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Not yet recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Intervention:   Drug: VX-509
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013

Condition:   Relapsed or Refractory Mantle Cell Lymphoma
Intervention:   Drug: Ibrutinib
Sponsors:   Janssen Biotech, Inc.;   Janssen Biotech, Inc.;   Pharmacyclics
Recruiting - verified June 2013

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: TL32711;   Drug: 5-Azacitidine
Sponsors:   TetraLogic Pharmaceuticals;   TetraLogic Pharmaceuticals
Not yet recruiting - verified April 2013

Condition:   HER2-Positive Early Stage Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Pegfilgrastim
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   GlaxoSmithKline
Recruiting - verified May 2013

Condition:   Hypertension, Pulmonary
Interventions:   Drug: Tadalafil;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Not yet recruiting - verified June 2013

Condition:   Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention:   Device: AMG 145
Sponsors:   Amgen;   Amgen
Not yet recruiting - verified June 2013

Condition:   Ovarian Cancer
Interventions:   Procedure: Positron Emission Tomography;   Radiation: 18F-Fluoro-2-deoxy-D-lucose;   Procedure: Cytoreductive surgery
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Interstitial Cystitis
Interventions:   Drug: LiRIS 400 mg;   Other: LiRIS Placebo
Sponsors:   TARIS Biomedical, Inc.;   TARIS Biomedical, Inc.
Recruiting - verified June 2013

Condition:   Bulimia Nervosa
Intervention:  
Sponsors:   Drexel University;   Drexel University;   Columbia University;   The Miriam Hospital
Recruiting - verified May 2013

Condition:   Asthma
Interventions:   Drug: Placebo;   Drug: JNJ-38518168
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Not yet recruiting - verified June 2013

Conditions:   Muscular Dystrophy, Duchenne;   Muscular Dystrophies;   Muscular Disorders, Atrophic;   Muscular Diseases;   Musculoskeletal Diseases;   Neuromuscular Diseases;   Nervous System Diseases;   Genetic Diseases, X-Linked;   Genetic Diseases, Inborn
Interventions:   Drug: Ataluren;   Drug: Placebo
Sponsors:   PTC Therapeutics;   PTC Therapeutics
Recruiting - verified April 2013

Conditions:   Inflammatory Bowel Disease (IBD);   Primary Sclerosing Cholangitis (PSC);   Colorectal Neoplasms;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified June 2013

Condition:   Schizophrenia
Interventions:   Drug: Lurasidone;   Drug: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2;   Drug: Placebo
Sponsors:   Sunovion;   Sunovion
Recruiting - verified June 2013

Conditions:   HIV;   HIV Infections
Interventions:   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide;   Drug: E/C/F/TDF, EFV/FTC/TDF, ritonavir + atazanavir + FTC/TDF, or GS-9350 + atazanavir + FTC/TDF
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified May 2013

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Janssen Scientific Affairs, LLC;   Bayer Pharma AG
Recruiting - verified May 2013

Condition:   Phenylketonuria
Intervention:   Drug: BMN 165
Sponsors:   BioMarin Pharmaceutical;   BioMarin Pharmaceutical
Recruiting - verified June 2013

Conditions:   Multiple Myeloma;   Disease of the Marrow;   Osteoporosis
Intervention:  
Sponsors:   New York University School of Medicine;   New York University School of Medicine
Recruiting - verified June 2013

Condition:   Prostate Cancer
Interventions:   Drug: TAK-700;   Drug: Bicalutamide
Sponsors:   Southwest Oncology Group;   Southwest Oncology Group;   Millennium Pharmaceuticals, Inc.;   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions:   Drug: Ivacaftor;   Drug: Lumacaftor;   Drug: Ivacaftor Placebo;   Drug: Lumacaftor Placebo
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified June 2013

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
Intervention:   Drug: PCI-32765 (Ibrutinib)
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharmacyclics
Not yet recruiting - verified June 2013

Condition:   Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions:   Drug: Ivacaftor;   Drug: Lumacaftor;   Drug: Ivacaftor Placebo;   Drug: Lumacaftor Placebo
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified June 2013

Condition:   Chronic Hepatitis C Infection
Interventions:   Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin;   Drug: Placebo for Ribavirin
Sponsors:   AbbVie;   AbbVie
Recruiting - verified May 2013

Condition:   Pneumonia, Bacterial
Interventions:   Drug: Amikacin Inhalation Solution (BAY41-6551);   Drug: Aerosolized Placebo
Sponsors:   Bayer;   Bayer;   Nektar Therapeutics
Recruiting - verified May 2013

Condition:   Peripheral Arterial Disease
Interventions:   Drug: edoxaban;   Drug: Clopidogrel;   Drug: Aspirin
Sponsors:   Daiichi Sankyo Inc.;   Daiichi Sankyo Inc.;   UMC Utrecht
Recruiting - verified June 2013

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: RO5452802;   Drug: erlotinib [Tarceva]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Condition:   Spasticity
Intervention:   Drug: Baclofen
Sponsors:   Sun Pharma Advanced Research Company Limited;   Sun Pharma Advanced Research Company Limited
Recruiting - verified April 2013

Conditions:   Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions:   Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Sponsors:   GRADE Study Group;   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Becton, Dickinson and Company;   Bristol-Myers Squibb;   Merck;   Novo Nordisk;   Hoffmann-La Roche;   Sanofi
Recruiting - verified June 2013

Condition:   Giant Cell Arteritis
Interventions:   Drug: tocilizumab [RoActemra/Actemra];   Drug: tocilizumab [RoActemra/Actemra];   Drug: tocilizumab placebo;   Drug: prednisone;   Drug: prednisone placebo;   Drug: tocilizumab [RoActemra/Actemra]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified June 2013

Condition:   Pulmonary Arterial Hypertension
Intervention:  
Sponsors:   United Therapeutics;   United Therapeutics
Recruiting - verified June 2013

Condition:   Osteoarthritis
Interventions:   Device: Univers™;   Device: Eclipse™ Total Shoulder Replacement
Sponsors:   Arthrex, Inc.;   Arthrex, Inc.
Recruiting - verified May 2013

Condition:   Low Back Pain
Interventions:   Drug: Hydrocodone bitartrate extended-release tablets;   Drug: Matching placebo
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries
Recruiting - verified May 2013

Condition:   Hyperparathyroidism, Secondary
Interventions:   Drug: AMG 416;   Drug: Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Respiratory Infections, Acute
Intervention:   Device: Respiratory Inductive Plethysmography
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2013

Condition:   Osteoarthritis
Interventions:   Drug: Meloxicam Test Capsules;   Drug: Meloxicam Test Capsules;   Drug: Placebo Capsules
Sponsors:   Iroko Pharmaceuticals, LLC;   Iroko Pharmaceuticals, LLC
Recruiting - verified June 2013

Conditions:   Amyloidosis;   Systemic Light-Chain Amyloidosis
Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone
Sponsors:   Academic Myeloma Consortium;   Academic Myeloma Consortium;   Onyx Pharmaceuticals;   CORE Science Solutions;   Criterium Inc.
Recruiting - verified June 2013

Condition:   Hyperparathyroidism, Secondary
Interventions:   Drug: AMG 416;   Drug: Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Conditions:   Burkitt Lymphoma;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Mantle-Cell;   Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention:   Drug: SGN-CD19A
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified May 2013

Condition:   Hypertension, Pulmonary
Intervention:   Drug: Riociguat (BAY 63-2521)
Sponsors:   Bayer;   Bayer
Available - verified May 2013

Condition:   Papulopustular Rosacea
Interventions:   Drug: omiganan;   Drug: placebo
Sponsors:   Cutanea Life Sciences, Inc.;   Cutanea Life Sciences, Inc.
Recruiting - verified June 2013

Condition:   Allergic Rhinitis
Interventions:   Drug: BDP Nasal Aerosol;   Drug: Placebo
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries
Recruiting - verified May 2013

Conditions:   Coronary Artery Disease;   Angina Pectoris;   Cardiac Valve Disease
Interventions:   Device: SternaLock Blue closure system;   Device: Suture Wire
Sponsors:   Biomet, Inc.;   Biomet, Inc.
Recruiting - verified June 2013

Condition:   Idiopathic Parkinson's Disease
Interventions:   Drug: Rotigotine;   Other: Placebo
Sponsors:   UCB, Inc.;   UCB BIOSCIENCES GmbH
Recruiting - verified May 2013

Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Fatigue
Interventions:   Drug: armodafinil;   Other: Placebo
Sponsors:   Alliance for Clinical Oncology Trials;   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified January 2013

Condition:   Lymphoma
Intervention:   Drug: PCI-32765 (Ibrutinib)
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharmacyclics
Recruiting - verified June 2013

Condition:   Mantle Cell Lymphoma
Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharmacyclics
Recruiting - verified June 2013

Conditions:   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: brentuximab vedotin
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013

Condition:   Idiopathic Parkinson's Disease
Interventions:   Drug: CVT-301;   Drug: Placebo
Sponsors:   Civitas Therapeutics;   Civitas Therapeutics
Recruiting - verified June 2013

Condition:   NYHA Class IIIB/IV Patients Eligible for HeartMate II Implant Either as BTT or DT
Interventions:   Device: HeartMate II;   Drug: Pharmacological Treatment
Sponsors:   University of Louisville;   University of Louisville;   Thoratec Corporation
Recruiting - verified June 2013

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Regorafenib (BAY73-4506);   Drug: Placebo
Sponsors:   Bayer;   Bayer
Recruiting - verified May 2013

Condition:   Myelogenous Leukemia, Acute
Interventions:   Drug: RO5503781;   Drug: cytarabine
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Conditions:   Malignant Pleural Mesothelioma (MPM);   Choroidal Nevus;   Primary Uveal Melanoma (UM);   Metastatic Uveal Melanoma (UM)
Intervention:   Other: tumor specimens
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Breast Cancer
Interventions:   Drug: trastuzumab emtansine;   Drug: trastuzumab
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   German Breast Group
Recruiting - verified June 2013

Condition:   Migraine
Intervention:   Biological: ALD403
Sponsors:   Alder Biopharmaceuticals, Inc.;   Alder Biopharmaceuticals, Inc.
Recruiting - verified May 2013

Condition:   Crohns Disease
Interventions:   Biological: PDA001;   Drug: Vehicle Controlled Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2013

Condition:   Idiopathic Pulmonary Fibrosis
Interventions:   Drug: Simtuzumab (GS-6624);   Drug: Placebo
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified June 2013

Condition:   Acne Vulgaris
Interventions:   Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%;   Drug: Acanya® Gel, 1.2%/2.5%;   Drug: Vehicle of test product
Sponsors:   Taro Pharmaceuticals USA;   Taro Pharmaceuticals USA
Recruiting - verified June 2013

Condition:   Squamous Non Small Cell Lung Cancer
Interventions:   Drug: Necitumumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Conditions:   Transplantation;   Organ Transplantation;   Heart Transplantation
Interventions:   Drug: Bortezomib;   Procedure: Plasmapheresis on days 0, 1 and 2.
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation (CTOT)
Recruiting - verified June 2013

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Placebo;   Drug: Dulaglutide;   Drug: Glimepiride
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Type 2 Diabetes
Interventions:   Drug: lixisenatide (AVE0010);   Drug: insulin glulisine (HMR1964)
Sponsors:   Sanofi;   Sanofi
Recruiting - verified June 2013

Condition:   Erectile Dysfunction
Interventions:   Drug: avanafil;   Drug: Placebo
Sponsors:   VIVUS, Inc.;   VIVUS, Inc.
Recruiting - verified May 2013

Conditions:   Amnestic Mild Cognitive Impairment;   Alzheimer's Disease
Interventions:   Drug: Insulin (Humulin® R U-100);   Drug: Placebo
Sponsors:   Alzheimer's Disease Cooperative Study (ADCS);   Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified June 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: BAN2401 2.5 mg/kg;   Drug: BAN2401 5.0 mg/kg;   Drug: BAN2401 10 mg/kg;   Drug: BAN2401 5.0 mg/kg;   Drug: BAN2401 10 mg/kg
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified June 2013

Condition:   Dyslipidemia
Interventions:   Device: AMG 145;   Device: Placebo;   Drug: Atorvastatin
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Hyperlipidemia
Interventions:   Drug: AMG 145;   Other: Ezetimibe;   Other: Placebo (administered subcutaneously);   Other: Placebo (administered orally);   Drug: Statin therapy
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Hyperlipidemia
Interventions:   Drug: AMG 145;   Other: Placebo (administered subcutaneously);   Drug: Ezetimibe;   Other: Placebo (administered orally)
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Obesity
Interventions:   Device: Aspiration Therapy (AspireAssist);   Behavioral: Lifestyle Therapy
Sponsors:   Aspire Bariatrics, Inc.;   Aspire Bariatrics, Inc.;   Boston Medical Center;   Brigham and Women's Hospital;   Cornell University;   Howard University;   Mayo Clinic;   Northwestern University;   St. Mary Medical Center;   San Diego Veterans Healthcare System;   University of Pennsylvania;   Washington University School of Medicine
Recruiting - verified May 2013

Conditions:   Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention:   Drug: Bevacizumab
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Genentech
Recruiting - verified May 2013

Conditions:   Parkinson's Disease;   Motor Symptoms;   Akinesia;   Hypomobility;   Delayed Levadopa Onset
Interventions:   Drug: APOKYN;   Drug: L-dopa;   Drug: Trimethobenzamide
Sponsors:   US WorldMeds LLC;   US WorldMeds LLC;   Cape Cod Clinical Research Inc.;   ClinData Services, Inc.
Recruiting - verified June 2013

Condition:   Clinical Safety of the ProMRI Pacemaker System When Used Under Specific MRI Conditions.
Interventions:   Device: Patients with a ProMRI Pacemaker System;   Other: Magnetic Resonance Imaging (MRI) scan
Sponsors:   Biotronik, Inc.;   Biotronik, Inc.
Recruiting - verified May 2013

Condition:   Neuroblastoma
Intervention:   Biological: Hu3F8 With GM-CSF
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Cancer Patients First-ever Acute Ischemic Stroke
Interventions:   Drug: Enoxaparin;   Drug: Aspirin
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Conditions:   Low Back Pain;   Osteoarthritis;   Neuropathic Pain
Intervention:   Drug: EN3409
Sponsors:   Endo Pharmaceuticals;   Endo Pharmaceuticals;   BioDelivery Science International, Inc. (BDSI)
Recruiting - verified February 2013

Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Romidepsin;   Drug: Lenalidomide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Saint Francis/Mount Sinai Regional Cancer Center;   Weill Medical College of Cornell University;   Celgene Corporation;   Biologics, Inc
Recruiting - verified May 2013

Condition:   Metastatic or Recurrent Lesions in the Spine
Intervention:   Radiation: Ir-192 high dose rate (HDR)
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Drug: VX-509;   Drug: VX-509 matching placebo
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013

Conditions:   Cholesterol Ester Storage Disease (CESD);   Lysosomal Acid Lipase Deficiency
Interventions:   Drug: SBC-102 [sebelipase alfa] (1 mg/kg);   Drug: Placebo
Sponsors:   Synageva BioPharma Corp.;   Synageva BioPharma Corp.
Recruiting - verified June 2013

Condition:   Cytomegalovirus Infections
Interventions:   Drug: RG7667;   Drug: Placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2013

Condition:   Cervical Dystonia
Intervention:   Drug: Dysport
Sponsors:   Ipsen;   Ipsen
Not yet recruiting - verified May 2013

Condition:   Cervical Dystonia
Interventions:   Drug: Dysport;   Drug: Placebo, Up to 2mL
Sponsors:   Ipsen;   Ipsen
Recruiting - verified May 2013

Condition:   Diabetic Kidney Disease
Interventions:   Drug: BMS-813160;   Drug: Placebo matching with BMS-813160
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified June 2013

Condition:   All Conditions of Integrative Medicine Clinic Patients
Intervention:  
Sponsors:   Duke University;   Duke University;   The Bravewell Collaborative
Not yet recruiting - verified May 2013

Condition:   Prostate Cancer
Interventions:   Drug: Abiraterone acetate;   Drug: Abiraterone acetate plus degarelix;   Drug: Degarelix
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Janssen Pharmaceuticals;   OHSU Knight Cancer Institute;   Cancer Institute of New Jersey;   NorthShore University HealthSystem Research Institute;   Duke University;   Feinberg School of Medicine, Northwestern University;   Sidney Kimmel Comprehensive Cancer Center;   University of North Carolina;   Wayne State University
Recruiting - verified May 2013

Condition:   Malignant Solid Tumor - Malignant Nervous System Neoplasm
Intervention:   Drug: Cabazitaxel (XRP6258)
Sponsors:   Sanofi;   Sanofi
Recruiting - verified June 2013

Condition:   Chronic Migraine, Headaches
Intervention:   Biological: onabotulinumtoxinA
Sponsors:   Allergan;   Allergan
Recruiting - verified June 2013

Conditions:   Open-Angle Glaucoma;   Ocular Hypertension
Interventions:   Drug: BOL-303259-X;   Drug: Timolol;   Drug: BOL-303259-X
Sponsors:   Bausch & Lomb Incorporated;   Bausch & Lomb Incorporated
Recruiting - verified June 2013

Conditions:   Open-Angle Glaucoma;   Ocular Hypertension
Interventions:   Drug: BOL-303259-X;   Drug: Timolol;   Drug: BOL-303259-X
Sponsors:   Bausch & Lomb Incorporated;   Bausch & Lomb Incorporated
Recruiting - verified June 2013

Conditions:   Pancreas Cancer;   Liver Cancer
Intervention:   Other: Perihepatic Phlebotomy
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Fragile X Syndrome
Interventions:   Drug: RO4917523;   Drug: RO4917523;   Drug: Placebo
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Conditions:   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions:   Drug: broccoli sprout extract;   Other: placebo;   Other: laboratory biomarker analysis
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified May 2013

Condition:   Multiple Myeloma
Interventions:   Drug: SAR650984;   Drug: Lenalidomide
Sponsors:   Sanofi;   Sanofi
Recruiting - verified June 2013

Condition:   Postherpetic Neuralgia
Interventions:   Drug: Z160;   Drug: Placebo
Sponsors:   Zalicus;   Zalicus
Recruiting - verified June 2013

Condition:   Abortion
Intervention:  
Sponsors:   Gynuity Health Projects;   Gynuity Health Projects
Recruiting - verified May 2013

Condition:   Asthma
Interventions:   Drug: Albuterol Spiromax® 90 mcg/inhalation;   Drug: Placebo Spiromax
Sponsors:   Teva Pharmaceutical Industries;   Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified May 2013

Condition:   Multiple Myeloma
Interventions:   Drug: Pomalidomide;   Procedure: stem cell;   Drug: Dexamethasone
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Celgene Corporation;   Weill Medical College of Cornell University;   North Shore University Hospital;   Cancer Institute of New Jersey
Recruiting - verified June 2013

Condition:   Malignant Rhabdoid Tumors (MRT), Neuroblastoma
Intervention:   Drug: LEE011
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Acute Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions:   Device: CliniMACS® CD34 Reagent System;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit ATG;   Procedure: Double Umbilical Cord Blood Transplantation;   Procedure: Haplo-Identical Cord Transplantation
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Condition:   Cystic Fibrosis
Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
Sponsors:   Savara Inc.;   Savara Inc.;   Synteract, Inc.
Recruiting - verified June 2013

Condition:   Dry Eye
Interventions:   Drug: Lifitegrast;   Drug: Placebo
Sponsors:   SARcode Bioscience;   SARcode Bioscience
Recruiting - verified June 2013

Condition:   Heart Failure
Intervention:   Device: Device: Attain Performa Pacing Lead (along with a standard CRT-D system)
Sponsors:   Medtronic Cardiac Rhythm Disease Management;   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: AC-1204;   Drug: Placebo
Sponsors:   Accera, Inc.;   Accera, Inc.
Recruiting - verified June 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: MK-8931;   Drug: Placebo
Sponsors:   Merck;   Merck
Recruiting - verified May 2013

Condition:   Eisenmenger Syndrome
Interventions:   Drug: Macitentan 10 mg, oral tablet, to be taken once daily.;   Drug: Matching placebo oral tablet, to be taken once daily.
Sponsors:   Actelion;   Actelion
Recruiting - verified June 2013

Conditions:   Relapsed Acute Lymphoblastic Leukemia;   Relapsed Acute Myelogenous Leukemia
Intervention:   Drug: GNKG168
Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium
Recruiting - verified May 2013

Conditions:   Breast Cancer;   Endometrial Cancer
Interventions:   Other: HLA vaginal gel (HyaloGYN®),;   Behavioral: questionnaires
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Generalized Tonic Clonic Seizures
Interventions:   Drug: Pregabalin Dose Level 1;   Drug: Pregabalin Dose Level 2;   Drug: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Familial Amyloid Polyneuropathy
Interventions:   Drug: ISIS TTR Rx;   Drug: Placebo
Sponsors:   Isis Pharmaceuticals;   Isis Pharmaceuticals;   GlaxoSmithKline
Recruiting - verified June 2013

Condition:   Breast Neoplasms
Interventions:   Drug: PD-0332991;   Drug: Letrozole;   Drug: Placebo;   Drug: Letrozole
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: ELND005;   Drug: Placebo
Sponsors:   Elan Pharmaceuticals;   Elan Pharma International Limited;   Elan Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Lobular Breast Carcinoma in Situ;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Procedure: quality-of-life assessment
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified May 2013

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: 300 mg Oral Azacitidine;   Drug: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2013

Condition:   Brain Mass
Intervention:   Procedure: MRI with DTI and fMRI
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   New York Presbyterian Hospital;   Columbia University;   Weill Medical College of Cornell University
Recruiting - verified May 2013

Condition:   Venous Leg Ulcers
Interventions:   Biological: HP802-247;   Biological: Vehicle
Sponsors:   Healthpoint;   Healthpoint
Recruiting - verified May 2013

Condition:   3D Transesophageal and Transthoracic Echocardiogram
Interventions:   Procedure: transesophageal echocardiography (TEE);   Procedure: thermodilution;   Procedure: transthoracic echocardiography (TTE)
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Conditions:   Immune Thrombocytopenia;   Platelet Disorder
Interventions:   Drug: Eltrombopag;   Drug: Placebo
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University;   GlaxoSmithKline
Recruiting - verified June 2013

Condition:   Spinal Muscular Atrophy (SMA)
Intervention:  
Sponsors:   Ohio State University;   Ohio State University;   National Institute of Neurological Disorders and Stroke (NINDS);   Families of SMA;   Massachusetts General Hospital;   University of Iowa
Recruiting - verified June 2013

Condition:   Pulmonary Sarcoidosis
Interventions:   Biological: PD 0360324;   Other: Normal Saline for injection
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Conditions:   Completion of Three Dose Series of HPV;   Improvement in Vaccine Intervals Between HPV Doses
Interventions:   Other: Telephone reminder;   Other: Text Message reminder
Sponsors:   University of Rochester;   University of Rochester;   Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified June 2013

Condition:   Breast Cancer
Interventions:   Other: Educational DVD 1;   Other: Educational DVD 2
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions:   Biological: bevacizumab;   Radiation: intensity-modulated radiation therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: proton beam radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Melanoma
Interventions:   Drug: Talimogene laherparepvec plus ipilimumab;   Drug: Ipilimumab
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Chronic Sinusitis
Interventions:   Drug: S8 sinus implant;   Drug: continued nasal steroid spray
Sponsors:   Intersect ENT;   Intersect ENT
Recruiting - verified June 2013

Condition:   Type 2 Diabetes in Obese Subjects
Interventions:   Device: EndoBarrier;   Procedure: Sham Procedure
Sponsors:   GI Dynamics;   GI Dynamics
Recruiting - verified May 2013

Conditions:   Mucositis;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer
Interventions:   Drug: entolimod;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Not yet recruiting - verified June 2013

Conditions:   Pulmonary Hypertension;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Inhaled nitric oxide;   Other: Placebo
Sponsors:   INO Therapeutics;   INO Therapeutics
Recruiting - verified May 2013

Condition:   Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: QVA149;   Drug: Long acting muscarinic antagonist (LAMA);   Drug: Long acting B2 agonist (LABA);   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Condition:   Reduction of Hypertrophic Skin Scarring
Interventions:   Drug: PF-06473871;   Drug: PF-06473871
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Conditions:   Epilepsy;   Pregnancy
Intervention:  
Sponsors:   Emory University;   Emory University;   The EMMES Corporation
Recruiting - verified June 2013

Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: NNC 0129-0000-1003
Sponsors:   Novo Nordisk;   Novo Nordisk
Recruiting - verified June 2013

Condition:   Parkinson's Disease
Interventions:   Drug: Rasagiline;   Drug: Placebo
Sponsors:   Teva Pharmaceutical Industries;   Teva Branded Pharmaceutical Products, R&D Inc.
Recruiting - verified June 2013

Condition:   Autism
Interventions:   Behavioral: Playground Intervention;   Behavioral: STAT Intervention
Sponsors:   Health Resources and Services Administration (HRSA);   Health Resources and Services Administration (HRSA);   University of Rochester;   University of Pennsylvania
Recruiting - verified May 2013

Condition:   Non Small Cell Lung Cancer
Intervention:   Device: Circulating tumor cell chip
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Memorial Sloan-Kettering Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2013

Condition:   Unresectable or Metastatic Melanoma
Interventions:   Biological: BMS-936558;   Drug: Dacarbazine;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified May 2013

Condition:   Small Cell Lung Carcinoma
Interventions:   Drug: LY2940680;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Squamous Cell Non-small Cell Lung Cancer
Intervention:   Drug: Nivolumab (BMS-936558)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified May 2013

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention:   Drug: PCI-32765
Sponsors:   Pharmacyclics;   Pharmacyclics
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Placebo;   Drug: Baricitinib
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Placebo;   Drug: Baricitinib
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Major Depressive Disorder
Interventions:   Drug: LY2940094;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Conditions:   Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions:   Drug: Empagliflozin low dose qd;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Metformin 500 mg bid;   Drug: Empagliflozin high dose bid;   Drug: Empagliflozin low dose bid;   Drug: Metformin 1000 mg bid;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose bid
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals;   Eli Lilly and Company
Recruiting - verified June 2013

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions:   Drug: PCI-32765;   Drug: Chlorambucil
Sponsors:   Pharmacyclics;   Pharmacyclics
Recruiting - verified June 2013

Condition:   Binge Eating Disorder
Interventions:   Drug: SPD489 (Lisdexamfetamine dimesylate);   Drug: Placebo
Sponsors:   Shire Development LLC;   Shire Development LLC
Recruiting - verified May 2013

Condition:   Glottic Aperture
Intervention:   Device: Laryngoscope blade
Sponsors:   State University of New York at Buffalo;   State University of New York at Buffalo
Recruiting - verified June 2013

Condition:   Colorectal Cancer Metastatic
Interventions:   Drug: FOLFOX6m;   Device: SIR-Spheres microspheres
Sponsors:   Sirtex Medical;   Sirtex Medical
Recruiting - verified June 2013

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: Placebo
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Condition:   Women at Increased Risk for Developing Breast Carcinoma
Intervention:   Other: Mammography (CESM) and MRI
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2013

Condition:   Lupus Nephritis
Interventions:   Biological: BMS-188667;   Drug: Mycophenolate mofetil;   Drug: Prednisone;   Biological: Placebo matching with BMS-188667
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified June 2013

Condition:   CANCER,NOS
Interventions:   Drug: BMS-986015 (ANTI-KIR);   Drug: BMS-936558 (ANTI-PD1)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified June 2013

Condition:   Atrial Fibrillation
Interventions:   Drug: rivaroxaban;   Drug: uninterrupted vitamin K antagonist (VKA)
Sponsors:   Janssen Scientific Affairs, LLC;   Janssen Scientific Affairs, LLC
Recruiting - verified June 2013

Condition:   Asthma
Interventions:   Drug: QGE031;   Drug: Omalizumab;   Drug: Placebo to QGE031;   Drug: Placebo to omalizumab
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Condition:   Cystic Fibrosis
Interventions:   Drug: dornase alfa [Pulmozyme];   Drug: dornase alfa [Pulmozyme]
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: PF-05212377 (SAM-760);   Other: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Baricitinib;   Drug: Methotrexate;   Drug: Placebo;   Drug: Folic Acid
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Drug: Placebo;   Drug: Adalimumab;   Drug: Baricitinib
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Amyotrophic Lateral Sclerosis
Interventions:   Drug: CK-2017357;   Other: Placebo tablets
Sponsors:   Cytokinetics;   Cytokinetics
Recruiting - verified June 2013

Condition:   Systemic Lupus Erythematosus
Intervention:   Drug: Vitamin D3
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Autoimmunity Centers of Excellence
Recruiting - verified June 2013

Condition:   Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions:   Drug: GRT6005 Low-Dose Range;   Drug: GRT6005 High-Dose Range;   Drug: Placebo;   Drug: Oxycodone CR
Sponsors:   Forest Laboratories;   Forest Laboratories;   Grünenthal GmbH
Recruiting - verified May 2013

Condition:   Rheumatoid Arthritis
Interventions:   Drug: AIN457;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2013

Condition:   Retinal Hemangioma
Intervention:   Drug: Aflibercept
Sponsors:   Vitreous -Retina- Macula Consultants of New York;   Vitreous -Retina- Macula Consultants of New York;   Regeneron Pharmaceuticals
Available - verified June 2013

Condition:   Hodgkin Disease
Intervention:   Drug: brentuximab vedotin
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified May 2013

Condition:   Plaque Psoriasis
Interventions:   Drug: (CP-6890,550) Tofacitinib;   Drug: Placebo;   Drug: (CP-690,550) Tofacitinib;   Drug: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Postmenopausal Osteoporosis
Interventions:   Drug: Teriparatide;   Drug: Risedronate;   Drug: Placebo;   Drug: Calcium;   Drug: Vitamin D
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Healthy
Intervention:   Biological: DENVax
Sponsors:   Inviragen Inc.;   Inviragen Inc.;   Walter Reed Army Institute of Research (WRAIR)
Recruiting - verified June 2013

Conditions:   Recurrent Melanoma;   Recurrent Thyroid Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: cabozantinib-s-malate;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Drug: sarilumab SAR153191 (REGN88);   Other: placebo
Sponsors:   Sanofi;   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2013

Condition:   Primary Amyloidosis
Intervention:   Drug: NEOD001
Sponsors:   Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc;   Onclave Therapeutics Limited, a wholly-owned subsidiary of Prothena Corporation plc
Recruiting - verified May 2013

Condition:   Medulloblastoma
Interventions:   Drug: LDE225;   Drug: TMZ
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir + atazanavir + emtricitabine/tenofovir df
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified June 2013

Condition:   Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions:   Drug: RAD001;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2013

Condition:   Alzheimer's Disease
Intervention:   Drug: florbetapir (18F)
Sponsors:   Avid Radiopharmaceuticals;   Avid Radiopharmaceuticals;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Measles, Mumps and Rubella Diseases
Interventions:   Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2013

Condition:   Neuropathic Pain
Interventions:   Drug: pregabalin;   Drug: placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2013

Condition:   Advanced Solid Tumors, Excluding Breast Cancer
Interventions:   Drug: dovitinib (TKI258);   Drug: fluvoxamine
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Condition:   Chemotherapy-induced Nausea and Vomiting
Interventions:   Drug: Fosaprepitant 150 mg;   Drug: Fosaprepitant 60 mg;   Drug: Fosaprepitant 20 mg;   Drug: Placebo Fosaprepitant;   Drug: Ondansetron
Sponsors:   Merck;   Merck
Recruiting - verified May 2013

Condition:   Nausea
Interventions:   Device: Acupressure bands;   Other: Version 1 handout;   Behavioral: Version 1 MP3;   Other: Version 2 handout;   Behavioral: Version 2 MP3
Sponsors:   University of Rochester;   University of Rochester;   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified May 2013

Condition:   High Risk Acute Myeloid Leukemia
Interventions:   Drug: CPX-351;   Drug: 7+3 (cytarabine and daunorubicin)
Sponsors:   Celator Pharmaceuticals;   Celator Pharmaceuticals;   The Leukemia and Lymphoma Society
Recruiting - verified May 2013

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Tiotropium;   Drug: Placebo matching Olodaterol;   Drug: Tiotropium;   Drug: Olodaterol
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013

Condition:   Gastric Cancer
Interventions:   Drug: Rilotumumab;   Other: Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Malignant Melanoma
Intervention:   Biological: Ipilimumab
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified June 2013

Condition:   Psoriasis, Arthritic
Interventions:   Drug: ixekizumab;   Drug: Placebo;   Drug: Adalimumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Ulcerative Colitis
Interventions:   Biological: AMG 181;   Other: Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Moderate to Severe Plaque Psoriasis
Interventions:   Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: ustekinumab;   Drug: placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Fibromyalgia
Interventions:   Drug: TD-9855 Group 1;   Drug: TD-9855 Group 2;   Drug: Placebo
Sponsors:   Theravance, Inc.;   Theravance, Inc.
Recruiting - verified May 2013

Condition:   Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions:   Drug: fidaxomicin;   Drug: placebo
Sponsors:   Optimer Pharmaceuticals;   Optimer Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Psoriasis;   Psoriatic Arthritis
Interventions:   Drug: Apremilast 30 mg;   Drug: Etanercept 50 mg;   Drug: Placebo tablet;   Drug: Placebo injection (saline)
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2013

Conditions:   Sexually Transmitted Diseases;   Unsafe Sex;   Substance-Related Disorders
Interventions:   Behavioral: Connect II;   Behavioral: TAU
Sponsors:   Columbia University;   Columbia University;   National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified May 2013

Conditions:   PIK3CA Mutated Advanced Solid Tumors,;   PIK3CA Amplified Advanced Solid Tumors
Interventions:   Drug: BYL719;   Drug: AMG 479
Sponsors:   Novartis;   Novartis Pharmaceuticals;   Amgen
Recruiting - verified June 2013

Conditions:   Aortic Valve Stenosis;   Aortic Valve Stenosis With Insufficiency;   Regurgitation, Aortic Valve;   Aortic Valve Incompetence
Intervention:   Device: EDWARDS INTUITY valve
Sponsors:   Edwards Lifesciences;   Edwards Lifesciences
Recruiting - verified April 2013

Condition:   Adult Attention Deficit Hyperactivity Disorder
Interventions:   Drug: SEP-225289;   Drug: SEP-225289;   Drug: Placebo
Sponsors:   Sunovion;   Sunovion
Recruiting - verified June 2013

Condition:   Malignant Melanoma
Interventions:   Drug: vemurafenib;   Drug: Placebo;   Drug: GDC-0973
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Condition:   Chronic Anal Fissures
Interventions:   Drug: VEN 307;   Drug: Placebo
Sponsors:   Ventrus Biosciences, Inc;   Ventrus Biosciences, Inc
Recruiting - verified June 2013

Condition:   Lymphoma, B-Cell, Lymphoma, Follicular
Interventions:   Drug: DCDT2980S;   Drug: DCDS4501A;   Drug: rituximab [MabThera/Rituxan]
Sponsors:   Genentech;   Genentech
Recruiting - verified June 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: TRx0237 200 mg/day;   Drug: Placebo
Sponsors:   TauRx Therapeutics Ltd;   TauRx Therapeutics Ltd
Recruiting - verified May 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: TRx0237 150 mg/day;   Drug: TRx0237 250 mg/day;   Drug: Placebo
Sponsors:   TauRx Therapeutics Ltd;   TauRx Therapeutics Ltd
Recruiting - verified May 2013

Conditions:   Advanced Malignant Melanoma;   Renal Cell Carcinoma;   Non-small Cell Lung Cancer;   Colorectal Cancer
Intervention:   Drug: MEDI4736
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified June 2013

Condition:   Squamous Cell Carcinomas
Interventions:   Radiation: Reduced Dose Radiation;   Radiation: Standard Dose Radiation
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine;   The Biodesign Institute;   Arizona State University
Recruiting - verified June 2013

Condition:   Tuberculosis
Interventions:   Drug: rifapentine (M000473);   Drug: EFZ EMT TDF
Sponsors:   Sanofi;   Sanofi
Recruiting - verified June 2013

Condition:   Leukemia, Myeloid, Acute
Intervention:   Drug: BI 836858
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013

Condition:   Cardiovascular Diseases
Interventions:   Drug: Evacetrapib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   The Cleveland Clinic
Recruiting - verified June 2013

Condition:   Moderate to Severe Plaque Psoriasis
Interventions:   Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: ustekinumab;   Drug: placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Carotid Artery Disease
Intervention:   Device: MICHI NPS+f
Sponsors:   Silk Road Medical;   Silk Road Medical
Recruiting - verified June 2013

Condition:   Diabetic Kidney Disease
Interventions:   Drug: baricitinib;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   Incyte Corporation
Recruiting - verified June 2013

Condition:   Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: QVA149;   Drug: Long acting b2-agonist;   Drug: QVA149;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Osteoarthritis of the Knee;   Insomnia;   Knee Pain
Intervention:   Behavioral: Cognitive Behavioral Therapy for Insomnia
Sponsors:   University of Rochester;   University of Rochester;   National Institute on Aging (NIA)
Recruiting - verified May 2013

Condition:   Solid Tumor
Interventions:   Drug: Topotecan;   Drug: Sorafenib
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Pediatric Cancer Foundation;   Bayer
Recruiting - verified June 2013

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Disorders;   Chronic Myeloid Leukemia
Intervention:   Drug: EPZ-5676
Sponsors:   Epizyme, Inc.;   Epizyme, Inc.;   Celgene Corporation
Recruiting - verified June 2013

Conditions:   Leukemia;   Myelodysplastic Syndrome;   Lymphoma
Interventions:   Device: CliniMACS Fractionation system (Arm A);   Device: CliniMACS Fractionation system (Arm B)
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2013

Conditions:   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Other: flow cytometry;   Procedure: biopsy;   Other: immunohistochemistry staining method;   Genetic: western blotting
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified May 2013

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: LDK378
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Condition:   Congenital Heart Disease
Interventions:   Drug: Antithrombin III;   Drug: Placebo
Sponsors:   University of Rochester;   University of Rochester;   Grifols Therapeutics Inc.
Recruiting - verified June 2013

Condition:   Schizophrenia
Interventions:   Drug: ABT-126;   Drug: ABT-126;   Drug: Placebo
Sponsors:   AbbVie;   AbbVie (prior sponsor, Abbott)
Recruiting - verified June 2013

Condition:   Alzheimer Disease
Interventions:   Drug: RO4602522;   Drug: RO4601522;   Drug: placebo;   Drug: donepezil;   Drug: rivastigmine;   Drug: galantamine;   Drug: memantine
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Condition:   Neoplasms, Brain
Interventions:   Drug: Dabrafenib 3 mg/kg;   Drug: Dabrafenib 3.75 mg/kg;   Drug: Dabrafenib 4.5 mg/kg;   Drug: Dabrafenib 1.5 mg/kg;   Drug: Dabrafenib 2.25 mg/kg;   Drug: Dabrafenib (Final selected dose from Part 1)
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2013

Condition:   Bipolar Disorder
Interventions:   Drug: Ramelteon;   Drug: Placebo
Sponsors:   Takeda;   Takeda
Recruiting - verified June 2013

Condition:   Atrial Fibrillation
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonist (VKA)
Sponsors:   Bayer;   Bayer;   Janssen Research & Development, LLC
Recruiting - verified May 2013

Condition:   Low Back Pain
Intervention:   Drug: EN3409
Sponsors:   Endo Pharmaceuticals;   Endo Pharmaceuticals;   BDSI - BioDelivery Science International, Inc.
Recruiting - verified October 2012

Condition:   Bipolar 1 Disorder
Interventions:   Drug: ELND005;   Drug: Lamotrigine;   Drug: Valproic acid;   Drug: Placebo
Sponsors:   Elan Pharmaceuticals;   Elan Pharma International Limited;   Elan Pharmaceuticals
Recruiting - verified June 2013

Condition:   Non-Squamous Cell Non-small Cell Lung Cancer
Interventions:   Biological: BMS-936558;   Drug: Docetaxel
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified May 2013

Condition:   Renal Cell Carcinoma
Interventions:   Drug: SGN-75;   Drug: everolimus
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified May 2013

Condition:   Severe Aortic Stenosis
Intervention:   Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors:   Medtronic Cardiovascular;   Medtronic Cardiovascular
Recruiting - verified May 2013

Conditions:   Carcinoma, Renal Cell;   Renal Cell Carcinoma With Clear Cell Histology;   Renal Cell Carcinoma With Non-Clear Cell Histology;   Renal Cell Carcinoma of Papillary Histology
Intervention:   Drug: AGS-16C3F
Sponsors:   Astellas Pharma Inc;   Agensys, Inc.
Recruiting - verified June 2013

Condition:   Non-Alcoholic Steatohepatitis (NASH)
Interventions:   Biological: GS-6624 700mg;   Biological: GS-6624 200mg;   Biological: Placebo
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified May 2013

Condition:   Non-Alcoholic Steatohepatitis (NASH)
Interventions:   Biological: GS-6624 75 mg;   Biological: GS-6624 125 mg;   Biological: Placebo
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified May 2013

Condition:   Ischemic Dilated Cardiomyopathy (IDCM)
Interventions:   Biological: ixmyelocel-T;   Other: Vehicle Control
Sponsors:   Aastrom Biosciences;   Aastrom Biosciences
Recruiting - verified June 2013

Condition:   Breast Neoplasms
Intervention:   Drug: neratinib
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified June 2013

Condition:   Asperger's Syndrome, Healthy Volunteer, Autistic Disorder
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Conditions:   Metastatic Cancer or Locally Advanced;   Patients Receiving Palliative Radiation
Intervention:   Behavioral: questionnaires
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Prostate Cancer
Intervention:   Drug: Drug: 99mTc-MIP-1404
Sponsors:   Molecular Insight Pharmaceuticals, Inc.;   Molecular Insight Pharmaceuticals, Inc.
Recruiting - verified May 2013

Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: pegylated liposomal doxorubicin (PLD);   Drug: VTX-2337;   Drug: Placebo
Sponsors:   VentiRx Pharmaceuticals Inc.;   VentiRx Pharmaceuticals Inc.;   Gynecologic Oncology Group
Recruiting - verified June 2013

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: BI 695500;   Drug: BI 695500;   Drug: rituximab;   Drug: rituximab;   Drug: rituximab
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013

Condition:   Transplantation, Cytomegalovirus Infections
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: tiotropium bromide;   Drug: Placebo
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: tiotropium bromide;   Drug: Placebo
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013

Condition:   Acute Coronary Syndrome
Interventions:   Drug: SAR236553 (REGN727);   Other: placebo
Sponsors:   Sanofi;   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2013

Condition:   Anal Cancer
Intervention:   Biological: Advaxis
Sponsors:   Brown University;   Brown University;   Rhode Island Hospital;   The Miriam Hospital;   Montefiore Medical Center;   M.D. Anderson Cancer Center;   Boston Medical Center;   Ohio State University Comprehensive Cancer Center;   University of Pennsylvania
Recruiting - verified June 2013

Condition:   Lymphoma, Non-Hodgkin
Intervention:   Drug: BAY80-6946
Sponsors:   Bayer;   Bayer
Recruiting - verified May 2013

Condition:   Ulcerative Colitis
Interventions:   Drug: SAR339658;   Other: Placebo
Sponsors:   Sanofi;   Sanofi
Recruiting - verified June 2013

Conditions:   Deep Vein Thrombosis;   Venous Thrombosis
Interventions:   Drug: edoxaban tosylate;   Drug: enoxaparin/unfractionated heparin;   Drug: warfarin
Sponsors:   Daiichi Sankyo Inc.;   Daiichi Sankyo Inc.
Recruiting - verified June 2013

Condition:   Binge Eating Disorder
Intervention:   Drug: Lisdexamfetamine dimesylate
Sponsors:   Shire Development LLC;   Shire Development LLC
Recruiting - verified June 2013

Condition:   Venous Leg Ulcers
Interventions:   Biological: HP-802-247;   Biological: Vehicle
Sponsors:   Healthpoint;   Healthpoint;   Smith & Nephew, Inc.
Recruiting - verified June 2013

Condition:   Acute Decompensated Heart Failure
Interventions:   Drug: Ularitide;   Drug: Placebo
Sponsors:   Cardiorentis;   Cardiorentis;   Quintiles
Recruiting - verified June 2013

Condition:   Treatment Resistant Depression
Interventions:   Device: Low Frequency Magnetic Stimulation (LFMS);   Device: Sham LFMS
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Institute of Mental Health (NIMH);   Yale University;   Mount Sinai School of Medicine;   University of Texas Southwestern Medical Center;   University of Alabama at Birmingham;   Emory University
Recruiting - verified June 2013

Condition:   Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions:   Biological: CREON;   Biological: ZENPEP;   Biological: ULTRESA;   Biological: PANCREAZE;   Biological: other non-sponsor pancreatic enzyme replacement therapy;   Other: No pancreatic enzyme replacement therapy
Sponsors:   AbbVie;   AbbVie (prior sponsor, Abbott);   Aptalis Pharma;   Cystic Fibrosis Foundation;   Janssen Research & Development, LLC
Recruiting - verified May 2013

Conditions:   Genital Warts;   Anal Cancer;   Anal Intraepithelial Neoplasia
Intervention:   Biological: V503 Vaccine
Sponsors:   Merck;   Merck
Recruiting - verified May 2013

Condition:   Chronic Hepatitis B Infection
Interventions:   Drug: Tenofovir DF;   Drug: Tenofovir DF Placebo
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified February 2013

Condition:   Acute Appendicitis
Intervention:  
Sponsors:   Venaxis, Inc.;   Venaxis, Inc.
Recruiting - verified May 2013

Condition:   Carcinoma, Non-Small-Cell Lung
Intervention:   Drug: afatinib
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Available - verified June 2013

Condition:   Systemic Lupus Erythematosus
Interventions:   Drug: belimumab 10mg/kg;   Other: placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline;   Human Genome Sciences Inc., a GSK Company
Recruiting - verified May 2013

Conditions:   Estrogen Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: tamoxifen citrate;   Genetic: polymerase chain reaction;   Other: pharmacological study;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: pharmacogenomic studies;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Genetic: polymorphism analysis;   Procedure: therapeutic conventional surgery;   Genetic: nucleic acid sequencing;   Genetic: protein analysis
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: empagliflozin (low dose qd);   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Empagliflozin (high dose qd);   Drug: empagliflozin (high dose bid);   Drug: Placebo;   Drug: empagliflozin (low dose bid)
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   HIV Risk Reduction
Interventions:   Behavioral: supporting positive and healthy relationships;   Behavioral: community support group
Sponsors:   University of Rochester;   University of Rochester;   National Institute of Mental Health (NIMH)
Recruiting - verified June 2013

Conditions:   Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions:   Biological: anti-endoglin monoclonal antibody TRC105;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Cancer Free Women
Intervention:   Behavioral: questionnaire
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI);   University of Southern California
Recruiting - verified May 2013

Condition:   Chronic Myeloid Leukemia
Interventions:   Drug: ponatinib;   Drug: imatinib (Gleevec/ Glivec)
Sponsors:   Ariad Pharmaceuticals;   Ariad Pharmaceuticals
Recruiting - verified June 2013

Condition:   Long QT Syndrome
Interventions:   Drug: Placebo;   Drug: Ranolazine
Sponsors:   University of Rochester;   University of Rochester;   Gilead Sciences
Recruiting - verified June 2013

Condition:   Psoriasis
Interventions:   Drug: 80 mg ixekizumab;   Drug: 50 mg etanercept;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Conditions:   Non-Hodgkins Lymphoma;   B-cell Lymphoma;   Waldenstrom's Macroglobulinemia;   Marginal Zone Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Primary Central Nervous System Lymphoma
Intervention:   Drug: Ublituximab
Sponsors:   TG Therapeutics, Inc.;   TG Therapeutics, Inc.
Recruiting - verified June 2013

Condition:   Hypercholesterolemia
Interventions:   Drug: SAR236553 (REGN727);   Drug: matching placebo SAR236553 (REGN727);   Drug: Ezetimibe;   Drug: matching placebo for Ezetimibe
Sponsors:   Sanofi;   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2013

Condition:   Autism Spectrum Disorders
Interventions:   Other: Sham OMM;   Other: Osteopathic Manual Medicine (Body Therapy)
Sponsors:   New York Institute of Technology;   New York Institute of Technology
Recruiting - verified June 2013

Condition:   Cystic Fibrosis
Interventions:   Drug: Aztreonam for Inhalation Solution (AZLI);   Drug: Placebo
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified July 2012

Conditions:   Alcohol-Related Disorders;   Alcohol Use Disorders;   Alcohol Drinking;   Alcoholism;   Alcohol Abuse
Interventions:   Behavioral: Full Motivational Interviewing ("FMI");   Behavioral: Spirit Only Motivational Interviewing ("SOMI")
Sponsors:   Research Foundation for Mental Hygiene;   Research Foundation for Mental Hygiene;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified May 2013

Conditions:   Gastroesophageal Reflux Disease;   Erosive Esophagitis
Interventions:   Drug: Dexlansoprazole;   Drug: Dexlansoprazole;   Drug: Placebo
Sponsors:   Takeda;   Takeda
Recruiting - verified June 2013

Conditions:   Fibrolamellar Carcinoma;   Fibrolamellar Liver Cancer
Interventions:   Drug: everolimus;   Drug: letrozole plus leuprolide;   Drug: combination of everolimus, letrozole and leuprolide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   The Fibrolamellar Cancer Foundation;   Dana-Farber Cancer Institute/Brigham and Women¹s Cancer Center and Massachusetts General Hospital Cancer Center;   Johns Hopkins University;   University of California, San Francisco;   Abbott;   Novartis Pharmaceuticals
Recruiting - verified May 2013

Condition:   Gastroesophageal Reflux Disease
Intervention:   Drug: Dexlansoprazole
Sponsors:   Takeda;   Takeda
Recruiting - verified June 2013

Condition:   Ischemic Heart Failure
Interventions:   Biological: JVS-100 15 mg dose Injection;   Biological: Placebo Injection;   Biological: JVS-100 30 mg dose injection
Sponsors:   Juventas Therapeutics, Inc.;   Juventas Therapeutics, Inc.
Recruiting - verified May 2013

Conditions:   Recurrent Ovarian Cancer,;   Fallopian Tube Cancer
Intervention:   Drug: Intraoperative (hyperthermic) cisplatin followed by IP Cisplatin; Doxorubicin
Sponsors:   Columbia University;   Columbia University
Recruiting - verified May 2013

Conditions:   Breast Cancer;   HER-2 Positive Breast Cancer;   Triple Negative Breast Cancer
Intervention:   Drug: ganetespib
Sponsors:   Synta Pharmaceuticals Corp.;   Synta Pharmaceuticals Corp.
Recruiting - verified May 2013

Conditions:   Inflammation;   Rheumatoid Arthritis
Interventions:   Drug: NNC0109-0012;   Drug: placebo
Sponsors:   Novo Nordisk;   Novo Nordisk
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Biological: Rituximab-Pfizer (PF-05280586) x 3 courses;   Biological: Rituximab-EU+ Rituximab-Pfizer x 2 Courses;   Biological: Rituximab-US + Rituximab-Pfizer x 2 Courses
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Conditions:   Degenerative Sacroiliitis;   Sacroiliac Joint Disruption
Intervention:  
Sponsors:   SI-BONE, Inc.;   SI-BONE, Inc.
Recruiting - verified June 2013

Conditions:   Uncontrolled Hypertension;   Atrial Fibrillation
Intervention:   Device: Renal sympathetic denervation
Sponsors:   Mount Sinai School of Medicine;   Vivek Reddy
Recruiting - verified May 2013

Condition:   Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions:   Drug: fingolimod;   Drug: copaxone
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Condition:   Leukemia, Myeloid, Acute
Intervention:   Biological: CSL362
Sponsors:   CSL Limited;   CSL Limited;   Parexel
Recruiting - verified June 2013

Condition:   Osteoarthritis, Hip
Intervention:  
Sponsors:   North Shore Long Island Jewish Health System;   North Shore Long Island Jewish Health System
Recruiting - verified May 2013

Condition:   Perennial Allergic Rhinitis (PAR)
Intervention:   Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries;   United BioSource Corporation
Recruiting - verified May 2013

Condition:   Acne Vulgaris
Interventions:   Drug: CB-03-01;   Drug: Vehicle;   Drug: CB-03-01
Sponsors:   Intrepid Therapeutics, Inc.;   Intrepid Therapeutics, Inc.
Recruiting - verified June 2013

Conditions:   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Interventions:   Drug: ABT-199;   Drug: Rituximab
Sponsors:   AbbVie;   AbbVie (prior sponsor, Abbott);   Genentech
Recruiting - verified May 2013

Condition:   Parkinson's Disease
Intervention:  
Sponsors:   National Parkinson Foundation;   National Parkinson Foundation
Recruiting - verified May 2013

Condition:   Osteonecrosis of the Jaw (ONJ)
Intervention:  
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Major Depressive Disorder
Interventions:   Drug: Placebo;   Drug: Ketamine
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified June 2013

Condition:   Osteoarthritis, Knee
Intervention:   Device: TKA with Journey II BCS Total Knee System
Sponsors:   Smith & Nephew, Inc.;   Smith & Nephew, Inc.
Recruiting - verified June 2013

Conditions:   Mitral Regurgitation;   Mitral Valve Regurgitation
Intervention:   Device: MitraClip System
Sponsors:   Evalve;   Evalve;   Abbott Vascular
Recruiting - verified May 2013

Condition:   Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions:   Drug: TRx0237;   Drug: Placebo
Sponsors:   TauRx Therapeutics Ltd;   TauRx Therapeutics Ltd
Recruiting - verified May 2013

Condition:   Narcolepsy
Intervention:   Drug: Armodafinil
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries
Recruiting - verified May 2013

Conditions:   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Tumors Metastatic to Brain
Interventions:   Drug: lapatinib ditosylate;   Radiation: whole-brain radiation therapy
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified March 2013

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Measles, Mumps and Rubella Diseases
Interventions:   Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™);   Biological: Kinrix®;   Biological: Varivax®
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2013

Condition:   Ulcerative Colitis
Interventions:   Drug: PF-00547659 SC Injection;   Drug: PF-00547659 SC Injection;   Drug: PF-00547659 SC Injection;   Drug: PF-00547659 SC Injection;   Drug: PF-00547659 SC Injection
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Effect of Treatment on Bone Mineral Density
Interventions:   Drug: enclomiphene citrate;   Drug: Placebo
Sponsors:   Repros Therapeutics Inc.;   Repros Therapeutics Inc.
Recruiting - verified June 2013

Condition:   Idiopathic Pulmonary Fibrosis
Interventions:   Biological: Tralokinumab;   Biological: Tralokinumab;   Other: Placebo
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified May 2013

Condition:   Myelogenous Leukemia, Acute
Interventions:   Drug: RO5045377;   Drug: RO5045377;   Drug: cytarabine;   Drug: cytarabine
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Condition:   Hypercholesterolaemia
Interventions:   Drug: SAR236553 (REGN727);   Drug: placebo
Sponsors:   Sanofi;   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2013

Condition:   Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention:   Biological: Darbepoetin alfa
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:   Drug: BIBF 1120
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013

Condition:   Prostate Cancer
Interventions:   Drug: GTx-758 125 mg;   Drug: GTx-758 250 mg;   Drug: GTx-758 500 mg
Sponsors:   GTx;   GTx
Recruiting - verified June 2013

Condition:   Cervical Cancer
Intervention:   Other: DCE-MRI and 18F-FMISO PET
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Cytomegalovirus Infections
Intervention:   Drug: Maribavir
Sponsors:   ViroPharma;   ViroPharma
Recruiting - verified June 2013

Condition:   Herpes Zoster (HZ)
Interventions:   Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified June 2013

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel + LCL161;   Drug: paclitaxel
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: TAK-875;   Drug: TAK-875 Placebo
Sponsors:   Takeda;   Takeda
Recruiting - verified June 2013

Condition:   Emphysema
Intervention:   Device: PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Sponsors:   PneumRx, Inc.;   PneumRx, Inc.
Recruiting - verified December 2012

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: Sirukumab;   Drug: Sirukumab;   Drug: Sirukumab
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified June 2013

Condition:   Postmenopausal Women With Osteoporosis
Interventions:   Drug: AMG 785;   Drug: Alendronate
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Condition:   Healthy Adult Normals
Interventions:   Drug: BMS-933043;   Drug: Placebo matching with BMS-933043;   Drug: Antacid Buffer Predose Solution
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified May 2013

Conditions:   Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions:   Drug: cabozantinib;   Drug: prednisone
Sponsors:   Exelixis;   Exelixis
Recruiting - verified June 2013

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: gemcitabine;   Drug: placebo;   Drug: M402
Sponsors:   Momenta Pharmaceuticals, Inc.;   Momenta Pharmaceuticals, Inc.
Recruiting - verified June 2013

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: Sirukumab;   Drug: Sirukumab;   Drug: Sirukumab
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified June 2013

Conditions:   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Childhood Pineal Parenchymal Tumor
Interventions:   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide
Sponsors:   Children's Oncology Group;   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Female Orgasmic Disorder
Interventions:   Drug: Placebo;   Drug: Low dose TBS-2;   Drug: Medium dose TBS-2;   Drug: High dose TBS-2
Sponsors:   Trimel Biopharma SRL;   Trimel Biopharma SRL
Recruiting - verified June 2013

Condition:   Acute Kidney Injury
Interventions:   Biological: AC607;   Biological: Vehicle Only
Sponsors:   AlloCure Inc.;   AlloCure Inc.
Recruiting - verified June 2013

Condition:   Pancreatic Neuroendocrine Cancer
Intervention:   Other: MRI
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2013

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions:   Drug: Ibrutinib;   Drug: Bendamustine hydrochloride;   Drug: Rituximab;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharmacyclics
Recruiting - verified June 2013

Condition:   Breast Cancer
Interventions:   Drug: BKM120 Matching placebo;   Drug: Fulvestrant;   Drug: BKM120
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2013

Condition:   Melanoma
Interventions:   Drug: Dabrafenib;   Drug: Vemurafenib;   Drug: Trametinib
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified June 2013

Condition:   Psoriasis
Interventions:   Drug: 80 mg ixekizumab Dosing Regimen;   Drug: 50 mg etanercept;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Conditions:   Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma
Interventions:   Radiation: total-body irradiation (TBI);   Drug: thiotepa;   Drug: fludarabine phosphate;   Drug: melphalan;   Biological: anti-thymocyte globulin;   Procedure: allogeneic hematopoietic stem cell transplantation;   Biological: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2013

Condition:   Systemic Lupus Erythematosus
Interventions:   Biological: Belimumab plus Early Vaccination;   Biological: Belimumab plus Late Vaccination
Sponsors:   GlaxoSmithKline;   Human Genome Sciences Inc., a GSK Company;   GlaxoSmithKline
Recruiting - verified February 2013

Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Myelogenous Leukemia
Intervention:   Biological: Nivolumab
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified May 2013

Condition:   Gastric Cancer
Interventions:   Drug: onartuzumab;   Drug: Placebo;   Drug: mFOLFOX6
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Genentech
Recruiting - verified June 2013

Condition:   Neoplasms, Hematologic
Intervention:   Drug: 120 mg LY2784544
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Fibromyalgia
Interventions:   Drug: Tramadol;   Drug: Placebo;   Behavioral: Cognitive Behavior Therapy for FM;   Behavioral: Health Education
Sponsors:   University of Washington;   University of Washington
Recruiting - verified June 2013

Condition:   Solid Tumors
Interventions:   Drug: Iniparib (SAR240550/BSI-201);   Drug: Carboplatin;   Drug: Doxorubicin HCL liposome injection;   Drug: Gemcitabine;   Drug: Irinotecan;   Drug: Paclitaxel;   Drug: Topotecan
Sponsors:   Sanofi;   Sanofi
Recruiting - verified June 2013

Conditions:   Hepatitis B;   HBV
Interventions:   Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified May 2013

Condition:   Liver Cancer
Interventions:   Procedure: Standard fluid management;   Device: Goal directed fluid therapy with the Edwards EV1000 system
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Hepatitis B
Interventions:   Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified May 2013

Condition:   Bladder Cancer
Intervention:   Drug: Gemcitabine and Cisplatin (DD GC)
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   University of North Carolina, Chapel Hill;   New York University
Recruiting - verified June 2013

Condition:   Breast Cancer
Intervention:   Other: Radiation Therapy
Sponsors:   New York University School of Medicine;   New York University School of Medicine
Recruiting - verified June 2013

Condition:   ALK-Rearranged Non-Small Cell Lung Cancer
Interventions:   Drug: CH5424802;   Drug: CH5424802
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche;   Chugai Pharmaceutical
Recruiting - verified June 2013

Condition:   Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Interventions:   Biological: Ipilimumab;   Other: Best Supportive care (BSC)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified June 2013

Condition:   Distal Radius Fracture
Interventions:   Procedure: Open Reduction and Internal Fixation;   Procedure: External Fixation;   Procedure: Percutaneous Pinning;   Procedure: Closed Reduction and casting
Sponsors:   University of Michigan;   University of Michigan;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   National Institute on Aging (NIA)
Recruiting - verified May 2013

Condition:   Melanoma
Interventions:   Drug: dabrafenib plus trametinib;   Drug: dabrafenib plus trametinib placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2013

Conditions:   Myelodysplastic Syndrome;   MDS;   Trisomy 8
Intervention:   Drug: rigosertib
Sponsors:   Onconova Therapeutics, Inc.;   Onconova Therapeutics, Inc.
Recruiting - verified June 2013

Conditions:   Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Standard Treatment;   Biological: AGS-003
Sponsors:   Argos Therapeutics;   Argos Therapeutics
Recruiting - verified June 2013

Condition:   Renal Cancer
Intervention:   Drug: 124IcG250
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Wilex
Recruiting - verified June 2013

Condition:   Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Intervention:   Drug: IncobotulinumtoxinA
Sponsors:   Merz Pharmaceuticals GmbH;   Merz Pharmaceuticals GmbH
Recruiting - verified June 2013

Condition:   Venous Thromboembolism (VTE)
Interventions:   Drug: Betrixaban;   Drug: Enoxaparin
Sponsors:   Portola Pharmaceuticals;   Portola Pharmaceuticals
Recruiting - verified June 2013

Condition:   HIV Infections
Interventions:   Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013

Condition:   Age-Related Maculopathy
Interventions:   Biological: RN6G;   Biological: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Asthma
Interventions:   Drug: Fluticasone propionate DPI Dose 1;   Drug: Fluticasone propionate DPI Dose 2;   Drug: Fluticasone propionate DPI Dose 3;   Drug: Fluticasone propionate DPI Dose 4;   Other: Placebo DPI;   Drug: Flovent Diskus 250 mcg
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries
Recruiting - verified May 2013

Conditions:   Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour
Interventions:   Drug: Octreotide;   Drug: Octreotide;   Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors:   Advanced Accelerator Applications;   Advanced Accelerator Applications;   Pierrel Research Europe GmbH
Recruiting - verified June 2013

Condition:   Prostate Cancer
Interventions:   Drug: cabazitaxel, prednisone, custirsen sodium;   Drug: cabazitaxel, prednisone
Sponsors:   OncoGenex Technologies;   OncoGenex Technologies;   Teva Pharmaceutical Industries
Recruiting - verified May 2013

Condition:   Huntington's Disease
Intervention:  
Sponsors:   CHDI Foundation, Inc.;   CHDI Foundation, Inc.
Recruiting - verified May 2013

Condition:   Smoking Cessation
Interventions:   Drug: placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2013

Condition:   Small Cell Lung Carcinoma
Interventions:   Drug: BAY1000394;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Carboplatin
Sponsors:   Bayer;   Bayer
Recruiting - verified May 2013

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: BKM120 matching placebo;   Drug: BKM120
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Chronic Pain;   Low Back Pain;   Analgesia
Interventions:   Drug: ALO-02;   Drug: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2013

Condition:   Colorectal Cancer Metastatic
Interventions:   Drug: AFLIBERCEPT AVE0005;   Drug: FOLFIRI
Sponsors:   Sanofi;   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified June 2013

Condition:   Multiple Myeloma
Interventions:   Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
Sponsors:   Onyx Pharmaceuticals;   Onyx Pharmaceuticals
Recruiting - verified June 2013

Condition:   Hemophilia A
Intervention:   Biological: BAY94-9027
Sponsors:   Bayer;   Bayer
Recruiting - verified May 2013

Condition:   Bipolar I Disorder
Intervention:   Drug: Lurasidone
Sponsors:   Sunovion;   Sunovion
Recruiting - verified May 2013

Condition:   Schizophrenia
Intervention:   Drug: Lurasidone
Sponsors:   Sunovion;   Sunovion
Recruiting - verified May 2013

Condition:   Myelodysplastic Syndrome
Interventions:   Drug: Oral Azacitidine;   Drug: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2013

Condition:   Acute Lymphoblastic Leukemia
Interventions:   Drug: inotuzumab ozogamicin;   Drug: FLAG (fludarabine, cytarabine and G-CSF);   Drug: HIDAC (high dose cytarabine);   Drug: cytarabine and mitoxantrone
Sponsors:   Pfizer;   Pfizer;   Union Chimique Belge
Recruiting - verified June 2013

Conditions:   Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
Interventions:   Drug: MLN9708 + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013

Condition:   Alzheimer's Disease
Interventions:   Drug: LY2886721;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified June 2013

Condition:   Celiac Disease
Intervention:  
Sponsors:   Alvine Pharmaceuticals Inc.;   Alvine Pharmaceuticals Inc.
Recruiting - verified May 2013

Condition:   Epilepsy
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Condition:   Major Depressive Disorder, Recurrent
Interventions:   Drug: MK-6096;   Drug: Placebo
Sponsors:   Merck;   Merck
Recruiting - verified May 2013

Conditions:   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Intervention:   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Sjögren's Syndrome
Interventions:   Biological: Baminercept;   Other: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013

Condition:   Irritable Bowel Syndrome
Interventions:   Drug: JNJ-27018966;   Drug: Placebo
Sponsors:   Furiex Pharmaceuticals, Inc;   Furiex Pharmaceuticals, Inc
Recruiting - verified June 2013

Condition:   Juvenile Idiopathic Arthritis (JIA)
Intervention:   Drug: Certolizumab Pegol (CZP)
Sponsors:   UCB, Inc.;   UCB BIOSCIENCES GmbH
Recruiting - verified June 2013

Condition:   Glycemic Control
Interventions:   Drug: TAK-875;   Drug: Sitagliptin;   Drug: Placebo
Sponsors:   Takeda;   Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified June 2013

Condition:   Attention-deficit/Hyperactivity Disorder
Interventions:   Drug: Lisdexamfetamine dimesylate;   Drug: Methylphenidate Hydrochloride;   Drug: Placebo
Sponsors:   Shire Development LLC;   Shire Development LLC
Recruiting - verified May 2013

Conditions:   Infertility;   Recurrent Pregnancy Loss
Interventions:   Genetic: PGD;   Procedure: PGD
Sponsors:   Reprogenetics;   Reprogenetics;   Reprogenetics, Livingston, NJ;   Long Island IVF, Melville, NY;   Reproductive Associates of Illinois, Highland Park, IL;   Yale University;   McGill University;   BlueGnome, Cambridge, UK;   Southern California Reproductive Center, CA
Recruiting - verified May 2013

Condition:   Solid Cancers
Intervention:   Drug: Vismodegib
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2013

Conditions:   Chronic Inflammatory Demyelinating Polyneuropathy;   Polyradiculoneuropathy
Interventions:   Biological: IgPro20;   Biological: Placebo
Sponsors:   CSL Behring;   CSL Behring;   Parexel
Recruiting - verified May 2013

Conditions:   Cholangiocarcinoma;   Biliary Stricture;   Biliary Obstruction;   Bile Duct Cancer
Intervention:   Procedure: Photodynamic Therapy
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: PF-04449913;   Drug: Low dose ARA-C (LDAC);   Drug: PF-04449913;   Drug: Decitabine;   Drug: PF-04449913;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Pf-04449913;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: PF-04449913;   Drug: Low dose ARA-C (LDAC)
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Hepatitis C, Chronic
Interventions:   Biological: peginterferon alfa-2a;   Drug: ribavirin;   Drug: boceprevir
Sponsors:   Merck;   Merck
Recruiting - verified May 2013

Condition:   Magnetic Resonance Imaging
Intervention:   Drug: Gadobutrol (Gadavist, BAY86-4875)
Sponsors:   Bayer;   Bayer
Recruiting - verified May 2013

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: PH-797804;   Drug: PH-797804;   Drug: PH-797804;   Drug: PH-797804;   Drug: PH-797804;   Drug: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Condition:   Irritable Bowel Syndrome With Diarrhea
Interventions:   Drug: rifaximin;   Drug: placebo
Sponsors:   Salix Pharmaceuticals;   Salix Pharmaceuticals
Recruiting - verified January 2013

Condition:   Prostate Cancer
Interventions:   Procedure: Core Needle TRUS Needle biopsy (Transrectal ultrasound);   Procedure: Core Needle MRI/US image fusion guided needle biopsy
Sponsors:   Philips Healthcare;   Philips Healthcare
Recruiting - verified May 2013

Condition:   Colorectal Neoplasms
Intervention:   Drug: Regorafenib (BAY73-4506)
Sponsors:   Bayer;   Bayer
Available - verified June 2013

Condition:   Crohn's Disease
Interventions:   Drug: GSK1605786A;   Drug: GSK1605786A
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified June 2013

Conditions:   Restless Legs Syndrome;   End-Stage Renal Disease
Interventions:   Drug: Rotigotine;   Drug: Placebo
Sponsors:   UCB, Inc.;   UCB BIOSCIENCES GmbH
Recruiting - verified May 2013

Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Biological: trebananib;   Drug: cytarabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2013

Condition:   Multiple Myeloma
Interventions:   Drug: carfilzomib;   Drug: Dexamethasone;   Drug: Clarithromycin;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Lenalidomide
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University;   Onyx Therapeutics, Inc.
Recruiting - verified June 2013

Condition:   Prostate Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Condition:   Advanced Parkinson's Disease
Interventions:   Drug: Rotigotine;   Drug: Placebo
Sponsors:   UCB, Inc.;   UCB, Inc.
Recruiting - verified June 2013

Condition:   Cornea Tissue Preservation Time
Intervention:   Biological: Cornea tissue transplant
Sponsors:   Case Western Reserve University;   Case Western Reserve University;   National Eye Institute (NEI);   Jaeb Center for Health Research
Recruiting - verified May 2013

Conditions:   Esophageal Deviation;   Atrial Fibrillation;   Ablation
Intervention:   Procedure: esophageal deviation
Sponsors:   Mount Sinai School of Medicine;   Vivek Reddy;   Boston Scientific Corporation
Recruiting - verified May 2013

Conditions:   Diabetic Peripheral Neuropathy;   Pain
Interventions:   Drug: QUTENZA;   Drug: Placebo
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
Recruiting - verified June 2013

Condition:   Sclerosis, Systemic
Interventions:   Drug: tocilizumab [RoActemra/Actemra];   Drug: Placebo;   Drug: tocilizumab [RoActemra/Actemra]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified June 2013

Condition:   Adenoviral Conjunctivitis
Interventions:   Drug: NVC-422 Ophthalmic Solution, 0.33%;   Drug: Vehicle Ophthalmic Solution
Sponsors:   NovaBay Pharmaceuticals, Inc.;   NovaBay Pharmaceuticals, Inc.
Recruiting - verified June 2013

Condition:   Brain Cancer
Intervention:   Procedure: preoperative fMRI. DTI and DSI with tractography
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Schizophrenia
Interventions:   Drug: PP3M 175 mg eq.;   Drug: PP3M 263 mg eq.;   Drug: PP3M 350 mg eq.;   Drug: PP3M 525 mg eq.;   Drug: Placebo (20% Intralipid emulsion)
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified June 2013

Condition:   Severe Aortic Stenosis
Intervention:   Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Sponsors:   Medtronic Cardiovascular;   Medtronic Cardiovascular
Recruiting - verified May 2013

Conditions:   Solid Tumors;   Primary Brain Tumors
Interventions:   Drug: Vincristine sulfate;   Drug: Irinotecan;   Drug: Temozolomide;   Drug: Metformin
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Pediatric Cancer Foundation
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Biological: PF-05280586;   Biological: MabThera;   Biological: Rituxan
Sponsors:   Pfizer;   Pfizer
Recruiting - verified June 2013

Conditions:   22q13 Deletion Syndrome;   Phelan-McDermid Syndrome
Interventions:   Drug: Insulin-Like Growth Factor-1 (IGF-1);   Drug: Normal saline
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine
Recruiting - verified June 2013

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: afatinib;   Drug: erlotinib
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Unresectable Cholangiocarcinoma;   Biliary Obstruction;   Stent Obstruction;   Biliary Stricture
Intervention:   Procedure: Photodynamic Therapy
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified June 2013

Condition:   Hematopoietic Neoplasm
Intervention:   Drug: SAR302503
Sponsors:   Sanofi;   Sanofi
Recruiting - verified June 2013

Condition:   Lung Injury, Acute
Interventions:   Drug: Dose 1 GSK2586881;   Drug: Dose 2 GSK2586881;   Drug: Dose 3 GSK2586881;   Drug: Dose 4 GSK2586881;   Drug: Placebo (saline)
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2013

Conditions:   Metastatic Castration-resistant Prostate Cancer;   Metastatic Breast Cancer
Interventions:   Drug: Abiraterone acetate;   Drug: Abiraterone acetate
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified June 2013

Condition:   Prostatic Neoplasms
Intervention:   Drug: Radium-223 dichloride (BAY88-8223)
Sponsors:   Bayer;   Bayer
Available - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Biological: Certolizumab Pegol + Methotrexate (MTX);   Biological: Placebo + Methotrexate (MTX)
Sponsors:   UCB, Inc.;   UCB Pharma SA
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Biological: Certolizumab Pegol + Methotrexate (MTX);   Biological: Placebo + Methotrexate (MTX)
Sponsors:   UCB, Inc.;   UCB, Inc.
Recruiting - verified June 2013

Condition:   Metastatic Breast Cancer
Interventions:   Biological: OPT-822/OPT-821;   Biological: Phosphate Buffer Saline (PBS)
Sponsors:   OBI Pharma, Inc;   OBI Pharma, Inc
Recruiting - verified July 2012

Condition:   Orthostatic Hypotension
Interventions:   Drug: Midodrine HCl;   Drug: Placebo
Sponsors:   Shire Development LLC;   Shire Development LLC
Recruiting - verified May 2013

Condition:   Schizophrenia
Interventions:   Drug: PP3M 175 mg eq.;   Drug: PP3M 263 mg eq.;   Drug: PP3M 350 mg eq.;   Drug: PP3M 525 mg eq.;   Drug: Placebo (20% Intralipid);   Drug: PP1M 50 mg eq.;   Drug: PP1M 75 mg eq.;   Drug: PP1M 100 mg eq.;   Drug: PP1M 150 mg eq.
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified June 2013

Condition:   Psoriasis
Intervention:   Drug: etanercept
Sponsors:   Amgen;   Amgen
Recruiting - verified June 2013

Conditions:   Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions:   Drug: cabozantinib;   Drug: mitoxantrone;   Drug: prednisone
Sponsors:   Exelixis;   Exelixis
Recruiting - verified June 2013

Condition:   Suicidal Ideation
Interventions:   Drug: Ketamine;   Drug: Midazolam
Sponsors:   Mount Sinai School of Medicine;   James Murrough
Recruiting - verified June 2013

Conditions:   Diffuse Large B-cell Lymphoma;   Follicle Center Lymphoma
Intervention:   Drug: Zevalin (ibritumomab tiuxetan)
Sponsors:   Spectrum Pharmaceuticals, Inc;   Spectrum Pharmaceuticals, Inc
Recruiting - verified June 2013

Condition:   HIV Infection
Interventions:   Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Prevention Trials Network
Recruiting - verified June 2013

Condition:   HIV Infections
Intervention:   Drug: Etravirine (ETR)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2013

Conditions:   Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions:   Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)
Recruiting - verified June 2013

Conditions:   Brain Cancer;   Brain Stem Glioma
Intervention:   Radiation: Radioactive iodine-labeled monoclonal antibody 8H9
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Weill Medical College of Cornell University;   Johns Hopkins University
Recruiting - verified June 2013

Condition:   Acute Spinal Cord Injury
Interventions:   Drug: SUN13837 injection;   Drug: Placebo
Sponsors:   Asubio Pharmaceuticals, Inc.;   Asubio Pharmaceuticals, Inc.
Recruiting - verified June 2013

Condition:   Rheumatoid Arthritis
Interventions:   Biological: Certolizumab Pegol + Methotrexate (CZP + MTX);   Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors:   UCB, Inc.;   UCB Pharma SA
Recruiting - verified June 2013

Condition:   Melanoma
Intervention:   Procedure: Minimally invasive inguinal lymph node dissection
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified May 2013

Conditions:   Non-Hodgkin's Lymphoma;   Epstein-Barr Virus
Interventions:   Biological: EBV-specific T-cells;   Biological: EBV-specific T-cells
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified June 2013

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: entolimod;   Other: pharmacogenomic studies;   Other: pharmacological study;   Other: laboratory biomarker analysis
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Cleveland BioLabs
Recruiting - verified June 2013

Condition:   Diffuse Large B-Cell Lymphoma
Intervention:   Drug: Fostamatinib
Sponsors:   AstraZeneca;   AstraZeneca
Recruiting - verified June 2013

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: RO5490258;   Drug: bevacizumab [Avastin];   Drug: pemetrexed;   Drug: Placebo;   Drug: cisplatin/carboplatin;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2013

Condition:   Complicated Skin and Soft Tissue Infection
Interventions:   Drug: Ceftaroline fosamil;   Drug: Vancomycin;   Drug: Aztreonam
Sponsors:   AstraZeneca;   AstraZeneca;   Cerexa, Inc.
Recruiting - verified June 2013

Conditions:   Congenital Bleeding Disorder;   Haemophilia A
Intervention:   Drug: turoctocog alfa
Sponsors:   Novo Nordisk;   Novo Nordisk
Recruiting - verified June 2013

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: MM-398;   Drug: 5 Fluorouracil;   Drug: Leucovorin
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
Recruiting - verified June 2013

Conditions:   Locally Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: NKTR-102;   Drug: Treatment of Physician's Choice (TPC)
Sponsors:   Nektar Therapeutics;   Nektar Therapeutics
Recruiting - verified June 2013

Conditions:   Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention:   Drug: brentuximab vedotin
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2013

Condition:   ST Segment Elevation Myocardial Infarction
Interventions:   Biological: AMR-001;   Other: placebo
Sponsors:   Amorcyte, Inc.;   Amorcyte, Inc.
Recruiting - verified February 2013

Condition:   High-risk Smoldering Multiple Myeloma
Interventions:   Drug: Siltuximab;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified June 2013

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin
Sponsors:   Merck;   Merck
Recruiting - verified May 2013